3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: We evaluated the effects of 3-O-methyldopa (3-OMD), a metabolite of l-DOPA which is formed by catechol-O-methyltransferase (COMT), on the uptake, metabolism, and neuroprotective effects of l-DOPA in striatal astrocytes. We examined changes in the numbers of dopaminergic neurons after treatment with l-DOPA and 3-OMD or entacapone, a peripheral COMT inhibitor, using primary cultured mesencephalic neurons and striatal astrocytes. Results: The number of tyrosine hydroxylase-positive dopaminergic neurons was not affected by l-DOPA treatment in mesencephalic neurons alone. However, the increase in viability of dopaminergic neurons in the presence of astrocytes was further enhanced after methyl-l-DOPA treatment (25 μM) in mixed cultured mesencephalic neurons and striatal astrocytes. The neuroprotective effect of 25 μM l-DOPA was almost completely inhibited by simultaneous treatment with 3-OMD (10 or 100 μM), and was enhanced by concomitant treatment with entacapone (0.3 μM). The uptake of l-DOPA into and the release of glutathione from striatal astrocytes after l-DOPA treatment (100 μM) were inhibited by simultaneous exposure to 3-OMD (100 μM). Conclusions: These data suggest that l-DOPA exerts its neuroprotective effect on dopaminergic neurons via astrocytes and that 3-OMD competes with l-DOPA by acting on target molecule(s) (possibly including glutathione) released from astrocytes. Since some amount of entacapone can cross the blood-brain barrier, this reagent may enhance l-DOPA transportation by inhibiting COMT and increase the astrocyte-mediated neuroprotective effects of l-DOPA on dopaminergic neurons.

Original languageEnglish
Article number52
JournalBMC Neuroscience
Volume17
Issue number1
DOIs
Publication statusPublished - Jul 25 2016

Fingerprint

Dopamine Agents
Neuroprotective Agents
Astrocytes
Dopaminergic Neurons
Corpus Striatum
Catechol O-Methyltransferase
Neurons
Glutathione
3-O-methyl-DOPA
Tyrosine 3-Monooxygenase
Blood-Brain Barrier

Keywords

  • 3-O-Methyldopa
  • Astrocyte
  • Entacapone
  • Glutathione
  • l-DOPA

ASJC Scopus subject areas

  • Neuroscience(all)
  • Cellular and Molecular Neuroscience

Cite this

3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA. / Asanuma, Masato; Miyazaki, Ikuko.

In: BMC Neuroscience, Vol. 17, No. 1, 52, 25.07.2016.

Research output: Contribution to journalArticle

@article{a499847291de438fb3669c8508a51edb,
title = "3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA",
abstract = "Background: We evaluated the effects of 3-O-methyldopa (3-OMD), a metabolite of l-DOPA which is formed by catechol-O-methyltransferase (COMT), on the uptake, metabolism, and neuroprotective effects of l-DOPA in striatal astrocytes. We examined changes in the numbers of dopaminergic neurons after treatment with l-DOPA and 3-OMD or entacapone, a peripheral COMT inhibitor, using primary cultured mesencephalic neurons and striatal astrocytes. Results: The number of tyrosine hydroxylase-positive dopaminergic neurons was not affected by l-DOPA treatment in mesencephalic neurons alone. However, the increase in viability of dopaminergic neurons in the presence of astrocytes was further enhanced after methyl-l-DOPA treatment (25 μM) in mixed cultured mesencephalic neurons and striatal astrocytes. The neuroprotective effect of 25 μM l-DOPA was almost completely inhibited by simultaneous treatment with 3-OMD (10 or 100 μM), and was enhanced by concomitant treatment with entacapone (0.3 μM). The uptake of l-DOPA into and the release of glutathione from striatal astrocytes after l-DOPA treatment (100 μM) were inhibited by simultaneous exposure to 3-OMD (100 μM). Conclusions: These data suggest that l-DOPA exerts its neuroprotective effect on dopaminergic neurons via astrocytes and that 3-OMD competes with l-DOPA by acting on target molecule(s) (possibly including glutathione) released from astrocytes. Since some amount of entacapone can cross the blood-brain barrier, this reagent may enhance l-DOPA transportation by inhibiting COMT and increase the astrocyte-mediated neuroprotective effects of l-DOPA on dopaminergic neurons.",
keywords = "3-O-Methyldopa, Astrocyte, Entacapone, Glutathione, l-DOPA",
author = "Masato Asanuma and Ikuko Miyazaki",
year = "2016",
month = "7",
day = "25",
doi = "10.1186/s12868-016-0289-0",
language = "English",
volume = "17",
journal = "BMC Neuroscience",
issn = "1471-2202",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA

AU - Asanuma, Masato

AU - Miyazaki, Ikuko

PY - 2016/7/25

Y1 - 2016/7/25

N2 - Background: We evaluated the effects of 3-O-methyldopa (3-OMD), a metabolite of l-DOPA which is formed by catechol-O-methyltransferase (COMT), on the uptake, metabolism, and neuroprotective effects of l-DOPA in striatal astrocytes. We examined changes in the numbers of dopaminergic neurons after treatment with l-DOPA and 3-OMD or entacapone, a peripheral COMT inhibitor, using primary cultured mesencephalic neurons and striatal astrocytes. Results: The number of tyrosine hydroxylase-positive dopaminergic neurons was not affected by l-DOPA treatment in mesencephalic neurons alone. However, the increase in viability of dopaminergic neurons in the presence of astrocytes was further enhanced after methyl-l-DOPA treatment (25 μM) in mixed cultured mesencephalic neurons and striatal astrocytes. The neuroprotective effect of 25 μM l-DOPA was almost completely inhibited by simultaneous treatment with 3-OMD (10 or 100 μM), and was enhanced by concomitant treatment with entacapone (0.3 μM). The uptake of l-DOPA into and the release of glutathione from striatal astrocytes after l-DOPA treatment (100 μM) were inhibited by simultaneous exposure to 3-OMD (100 μM). Conclusions: These data suggest that l-DOPA exerts its neuroprotective effect on dopaminergic neurons via astrocytes and that 3-OMD competes with l-DOPA by acting on target molecule(s) (possibly including glutathione) released from astrocytes. Since some amount of entacapone can cross the blood-brain barrier, this reagent may enhance l-DOPA transportation by inhibiting COMT and increase the astrocyte-mediated neuroprotective effects of l-DOPA on dopaminergic neurons.

AB - Background: We evaluated the effects of 3-O-methyldopa (3-OMD), a metabolite of l-DOPA which is formed by catechol-O-methyltransferase (COMT), on the uptake, metabolism, and neuroprotective effects of l-DOPA in striatal astrocytes. We examined changes in the numbers of dopaminergic neurons after treatment with l-DOPA and 3-OMD or entacapone, a peripheral COMT inhibitor, using primary cultured mesencephalic neurons and striatal astrocytes. Results: The number of tyrosine hydroxylase-positive dopaminergic neurons was not affected by l-DOPA treatment in mesencephalic neurons alone. However, the increase in viability of dopaminergic neurons in the presence of astrocytes was further enhanced after methyl-l-DOPA treatment (25 μM) in mixed cultured mesencephalic neurons and striatal astrocytes. The neuroprotective effect of 25 μM l-DOPA was almost completely inhibited by simultaneous treatment with 3-OMD (10 or 100 μM), and was enhanced by concomitant treatment with entacapone (0.3 μM). The uptake of l-DOPA into and the release of glutathione from striatal astrocytes after l-DOPA treatment (100 μM) were inhibited by simultaneous exposure to 3-OMD (100 μM). Conclusions: These data suggest that l-DOPA exerts its neuroprotective effect on dopaminergic neurons via astrocytes and that 3-OMD competes with l-DOPA by acting on target molecule(s) (possibly including glutathione) released from astrocytes. Since some amount of entacapone can cross the blood-brain barrier, this reagent may enhance l-DOPA transportation by inhibiting COMT and increase the astrocyte-mediated neuroprotective effects of l-DOPA on dopaminergic neurons.

KW - 3-O-Methyldopa

KW - Astrocyte

KW - Entacapone

KW - Glutathione

KW - l-DOPA

UR - http://www.scopus.com/inward/record.url?scp=84979210744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979210744&partnerID=8YFLogxK

U2 - 10.1186/s12868-016-0289-0

DO - 10.1186/s12868-016-0289-0

M3 - Article

C2 - 27456338

AN - SCOPUS:84979210744

VL - 17

JO - BMC Neuroscience

JF - BMC Neuroscience

SN - 1471-2202

IS - 1

M1 - 52

ER -